The Niche Podcast

Join Dr. Noah Goodson every Monday for a summary of top news in the biotech, clinical research, and life science industries.

Monthly bonus episodes are interviews with industry experts and luminaries across the biotech, pharmaceuticals, life science, and clinical research space.

The Niche Episode 073 – Enzyvant, Charles River Laboratories, Merck (again), Regeneron

The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies
 

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-073-1
https://tinyurl.com/Niche-073-2
https://tinyurl.com/Niche-073-3
https://tinyurl.com/Niche-073-4
https://tinyurl.com/Niche-073-5
https://tinyurl.com/Niche-073-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

About the Show
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries. 

The Niche Episode 072 – Ginkgo, Neumora, Pfizer, GSK, Intergalactic, Voyager

Less than spiffy SPACs, big brains big money, Malaria buzz, vaccines, tests, series A, and Voyager gets a renewed lease on life

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-072-1
https://tinyurl.com/Niche-072-2
https://tinyurl.com/Niche-072-3
https://tinyurl.com/Niche-072-4
https://tinyurl.com/Niche-072-5
https://tinyurl.com/Niche-072-6
https://tinyurl.com/Niche-072-7
https://tinyurl.com/Niche-072-8

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

About the Show
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

 

The Niche Episode 071 – Merck (MSD), Merck KGaA, BioNTech, Kite

$11.5B acquisitions, we play “Who’s on First”, COVID19 therapy news, cancer Vaccines may be on the way, and CAR T for cancer is here to stay

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-071-1
https://tinyurl.com/Niche-071-2
https://tinyurl.com/Niche-071-3
https://tinyurl.com/Niche-071-4
https://tinyurl.com/Niche-071-5
https://tinyurl.com/Niche-071-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 070 – Incyte, Cue Health, Velocity, PROCEPT, Catalent

Double approval, double acquisition, $200M for tests, $200M for prostate robots, $450M for $1B worth of gummies

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-070-1
https://tinyurl.com/Niche-070-2
https://tinyurl.com/Niche-070-3
https://tinyurl.com/Niche-070-4
https://tinyurl.com/Niche-070-5
https://tinyurl.com/Niche-070-6
https://tinyurl.com/Niche-070-7

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 069 – BeiGene, Everest, Takeda, Exelixis, PerkinElmer + BioLegend, Prenetics

BeiGene’s oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-069-1
https://tinyurl.com/Niche-069-2
https://tinyurl.com/Niche-069-3
https://tinyurl.com/Niche-069-4
https://tinyurl.com/Niche-069-5
https://tinyurl.com/Niche-069-6
https://tinyurl.com/Niche-069-7
https://tinyurl.com/Niche-069-8

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon, Lycia, BlueBird + 2seventy, Mammoth

$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-068-1
https://tinyurl.com/Niche-068-2
https://tinyurl.com/Niche-068-3
https://tinyurl.com/Niche-068-4
https://tinyurl.com/Niche-068-5
https://tinyurl.com/Niche-068-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

 

About Instructor

If you'd like to comment on this course or lecture please Register or Login.

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.